Literature DB >> 21912267

First-year clinical outcomes in gender-mismatched heart transplant recipients.

Anne Jalowiec1, Kathleen L Grady, Connie White-Williams.   

Abstract

BACKGROUND: Research indicates that gender mismatch of organ donor and recipient may adversely affect outcomes in heart transplant (HT) patients. However, there is a paucity of literature on gender-mismatched outcomes in patients receiving an HT, and only a few outcomes have been investigated.
OBJECTIVES: Objectives were to (1) determine if gender-mismatched HT recipients experienced decreased survival, more posttransplantation complications, and more days of hospitalization during the first postoperative year as compared with gender-matched recipients and (2) identify risk factors for decreased survival.
METHODS: Patients were 347 HT recipients; 21.3% (74) received a heart from the opposite gender. Three groups were compared: group 1: same gender donor-recipient (273 [78.7%]: 36 women, 237 men); group 2: female donor-male recipient (40 [11.5%]); group 3: male donor-female recipient (34 [9.8%]). Ten outcomes were compared with Kaplan-Meier survival analysis, logistic regression, and multivariate analysis of covariance, using a Bonferroni-adjusted P ≤ .005. Risk factors for decreased survival were examined with Cox regression.
RESULTS: Gender-mismatched HT patients with a male donor and a female recipient (group 3) had more treated acute rejections and were rehospitalized for more days after HT discharge during the first postoperative year as compared with gender-matched patients. No significant differences were found in 8 other first-year outcomes: number of deaths, survival time, hospital length of stay for HT surgery, cardiac allograft vasculopathy, severe renal dysfunction, new-onset steroid-induced diabetes, nonskin cancers, or the number of infections treated with an intravenous antibiotic. Risk factors for decreased year 1 survival were higher year 1 cholesterol, earlier intravenous-treated infection, severe renal dysfunction, earlier treated rejection, and diabetes (both preexisting and new-onset steroid-induced diabetes).
CONCLUSION: Gender-mismatched HT recipients had more complications due to rejection and higher resource utilization due to more rehospitalization during the first postoperative year as compared with gender-matched recipients. Therefore, these problem areas may provide targets for possible interventions.

Entities:  

Mesh:

Year:  2012        PMID: 21912267      PMCID: PMC3247639          DOI: 10.1097/JCN.0b013e31822ce6c9

Source DB:  PubMed          Journal:  J Cardiovasc Nurs        ISSN: 0889-4655            Impact factor:   2.083


  43 in total

1.  Impact of gender mismatch on the outcome of heart transplantation.

Authors:  B Schlechta; A A Kocher; P Ofner; F Nourani; M Zimmerl; M Grimm; G Laufer
Journal:  Transplant Proc       Date:  1999-12       Impact factor: 1.066

2.  Hypercholesterolemia in long-term survivors of heart transplantation: an early marker of accelerated coronary artery disease.

Authors:  D Eich; J A Thompson; D J Ko; A Hastillo; R Lower; S Katz; M Katz; M L Hess
Journal:  J Heart Lung Transplant       Date:  1991 Jan-Feb       Impact factor: 10.247

3.  Increased rejection in gender-mismatched grafts: amelioration by triple therapy.

Authors:  A M Keogh; H A Valantine; S A Hunt; J S Schroeder; P E Oyer
Journal:  J Heart Lung Transplant       Date:  1991 Jan-Feb       Impact factor: 10.247

4.  The effect of donor gender on graft survival.

Authors:  Martin Zeier; Bernd Döhler; Gerhard Opelz; Eberhard Ritz
Journal:  J Am Soc Nephrol       Date:  2002-10       Impact factor: 10.121

5.  Three-year survival rates for all consecutive heart-only and lung-only transplants performed in Eurotransplant, 1997-1999.

Authors:  Jacqueline M A Smits; Johan Vanhaecke; Axel Haverich; Erwin de Vries; Mike Smith; Ellis Rutgrink; Annemarie Ramsoebhag; Alinde Hop; Guido Persijn; Gunther Laufer
Journal:  Clin Transpl       Date:  2003

6.  Oversizing of donor hearts: beneficial or detrimental?

Authors:  M R Costanzo-Nordin; Y L Liao; B B Grusk; E J O'Sullivan; R S Cooper; M R Johnson; K M Siebold; H J Sullivan; A H Heroux; J A Robinson
Journal:  J Heart Lung Transplant       Date:  1991 Sep-Oct       Impact factor: 10.247

Review 7.  Cardiac allograft vasculopathy after heart transplantation: risk factors and management.

Authors:  Hannah Valantine
Journal:  J Heart Lung Transplant       Date:  2004-05       Impact factor: 10.247

8.  Risk factor analysis for the major hazards following heart transplantation--rejection, infection, and coronary occlusive disease.

Authors:  L D Sharples; N Caine; P Mullins; J P Scott; E Solis; T A English; S R Large; P M Schofield; J Wallwork
Journal:  Transplantation       Date:  1991-08       Impact factor: 4.939

9.  Influence of traditional cardiovascular risk factors in the recipient on the development of cardiac allograft vasculopathy after heart transplantation.

Authors:  I J Sánchez Lázaro; L Almenar Bonet; J Moro López; E Sánchez Lacuesta; L Martínez-Dolz; J Agüero Ramón-Llín; L Andrés Lalaguna; O Cano Pérez; V Ortiz Martínez; F Buendía Fuentes; A Salvador Sanz
Journal:  Transplant Proc       Date:  2008-11       Impact factor: 1.066

10.  The impact of gender on heart transplantation outcomes: a single center experience.

Authors:  Luca Salvatore De Santo; Claudio Marra; Marisa De Feo; Cristiano Amarelli; Gianpaolo Romano; Maurizio Cotrufo
Journal:  Ital Heart J       Date:  2002-07
View more
  3 in total

1.  Mortality, rehospitalization, and post-transplant complications in gender-mismatched heart transplant recipients.

Authors:  Anne Jalowiec; Kathleen L Grady; Connie White-Williams
Journal:  Heart Lung       Date:  2017-05-10       Impact factor: 2.210

2.  Clinical outcomes in overweight heart transplant recipients.

Authors:  Anne Jalowiec; Kathleen L Grady; Connie White-Williams
Journal:  Heart Lung       Date:  2016-04-14       Impact factor: 2.210

Review 3.  Influence of Sex-Mismatch on Prognosis After Heart Transplantation.

Authors:  Ana Ayesta
Journal:  Front Cardiovasc Med       Date:  2021-03-25
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.